Deals channel feed – Endpoints News

Deals channel feed

Whisky, secrets, and code names: behind-the-scenes of Takeda's $62B Shire bid - Bloomberg

8 years ago

Playing catch-up, Eli Lilly swoops in with $1.6B cash deal for Armo Bio and its promising PhIII cancer drug

8 years ago

Takeda CEO Christophe Weber finally closes on his $62B deal to buy Shire — now he has to convince shareholders and slash jobs

8 years ago

Takeda closes in on a final $64B deal to buy Shire, starts to consider divestitures — reports

8 years ago

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

8 years ago

United Therapeutics bags rival SteadyMed for a bargain basement deal worth up to $216M, eliminating patent threat

8 years ago

What do you get when you integrate healthcare data from multiple sources into one comprehensive, global package? Travis May says he’s on track to find out

8 years ago

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters

8 years ago

Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal

8 years ago

Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion

8 years ago

After fruitless talks, a bid from Vas and plenty of patience, AveXis CEO Sean Nolan slowly reeled in an $8.7B deal

8 years ago

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire

8 years ago

On second thought, Allergan doesn't want to consider a bid for Shire, leaving Takeda in sole pursuit of $62.5B deal

8 years ago

Bidding war erupts for Shire as Takeda is stiff-armed on a $62.5B offer and Allergan jumps in

8 years ago

Joining a global M&A spree, Astellas reserves $2B for a spate of new biotech acquisitions

8 years ago

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

8 years ago

Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?

8 years ago

Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout

8 years ago

Novartis CEO Vas Narasimhan cuts loose an old anchor and sets sail with $8.7B AveXis buyout

8 years ago

With a deadline looming, Takeda CEO Weber woos analysts for support of a Shire buyout

8 years ago

Ferring buys up PhIII microbiome drug with acquisition of Rebiotix

8 years ago

Eyeing growth in regenerative medicine, Fujifilm spends $800M on two new members of its CDMO business

8 years ago

Could Takeda pull off a $50B-plus Shire takeover? Maybe, but analysts and investors have their doubts if they should

8 years ago

First page Previous page 108 109 110111112 113 114 Next page Last page